Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir Patent Expiration

Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir is Used for: Treatment of HCV infection. It was first introduced by Abbvie Inc in its drug Viekira Pak (Copackaged) on Dec 19, 2014.


Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir Patents

Given below is the list of patents protecting Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Viekira Pak (copackaged) US10201542 Formulations of pyrimidinedione derivative compounds Oct 18, 2033 Abbvie
Viekira Pak (copackaged) US6037157 Method for improving pharmacokinetics Jun 26, 2016

(Expired)

Abbvie
Viekira Pak (copackaged) US6703403 Method for improving pharmacokinetics Jun 26, 2016

(Expired)

Abbvie
Viekira Pak (copackaged) US7148359 Polymorph of a pharmaceutical Jul 19, 2019

(Expired)

Abbvie
Viekira Pak (copackaged) US7364752 Solid dispersion pharamaceutical formulations Nov 10, 2020

(Expired)

Abbvie
Viekira Pak (copackaged) US8188104 Anti-infective agents and uses thereof May 17, 2029 Abbvie
Viekira Pak (copackaged) US8268349 Solid pharmaceutical dosage form Aug 25, 2024 Abbvie
Viekira Pak (copackaged) US8399015 Solid pharmaceutical dosage form Aug 25, 2024 Abbvie
Viekira Pak (copackaged) US8420596 Macrocyclic hepatitis C serine protease inhibitors Apr 10, 2031 Abbvie
Viekira Pak (copackaged) US8466159 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Pak (copackaged) US8492386 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Pak (copackaged) US8501238 Anti-infective agents and uses thereof Dec 19, 2028 Abbvie
Viekira Pak (copackaged) US8642538 Macrocyclic hepatitis C serine protease inhibitors Sep 10, 2029 Abbvie
Viekira Pak (copackaged) US8680106 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Pak (copackaged) US8685984 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Pak (copackaged) US8686026 Solid compositions Jun 09, 2031 Abbvie
Viekira Pak (copackaged) US8691938 Anti-viral compounds Apr 13, 2032 Abbvie
Viekira Pak (copackaged) US9006387 Anti-viral compounds Jun 10, 2030 Abbvie
Viekira Pak (copackaged) US9044480 Compositions and methods for treating HCV Apr 10, 2031 Abbvie
Viekira Pak (copackaged) US9139536 Anti-infective agents and uses thereof Nov 09, 2028 Abbvie
Viekira Pak (copackaged) US9629841 Formulations of pyrimidinedione derivative compounds Oct 18, 2033 Abbvie


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir's patents.

Given below is the list recent legal activities going on the following patents of Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 12 Oct, 2023 US8188104
Payment of Maintenance Fee, 8th Year, Large Entity 08 Feb, 2023 US9139536
Payment of Maintenance Fee, 8th Year, Large Entity 09 Nov, 2022 US9044480
Payment of Maintenance Fee, 8th Year, Large Entity 14 Sep, 2022 US9006387
Payment of Maintenance Fee, 4th Year, Large Entity 13 Jul, 2022 US10201542
Patent Term Extension Certificate 19 Apr, 2022 US8501238
Payment of Maintenance Fee, 8th Year, Large Entity 09 Sep, 2021 US8691938
Payment of Maintenance Fee, 8th Year, Large Entity 09 Sep, 2021 US8686026
Payment of Maintenance Fee, 8th Year, Large Entity 15 Jul, 2021 US8642538
Notice of Final Determination -Eligible 16 Feb, 2021 US8501238



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳